Summary
ASCLEPIUS’s overall aim is to boost the scientific excellence and innovation capacity of Giorgi Eliava Institute of Bacteriophagy, Microbiology and Virology (Eliava) and its high-quality Twinning partners - l’Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Universidade do Minho and Intelligentsia Consultants Sarl – to expand their insights in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. To achieve this aim, ASCLEPIUS will implement a research and innovation strategy over three years based upon five objectives:
Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus.
Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners.
Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners.
Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes.
Objective 5: Raise the research profile of Eliava and the Twinning partners.
Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus.
Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners.
Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners.
Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes.
Objective 5: Raise the research profile of Eliava and the Twinning partners.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101159555 |
| Start date: | 01-10-2024 |
| End date: | 30-09-2027 |
| Total budget - Public funding: | - 1 493 420,00 Euro |
Cordis data
Original description
ASCLEPIUS’s overall aim is to boost the scientific excellence and innovation capacity of Giorgi Eliava Institute of Bacteriophagy, Microbiology and Virology (Eliava) and its high-quality Twinning partners - l’Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Universidade do Minho and Intelligentsia Consultants Sarl – to expand their insights in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. To achieve this aim, ASCLEPIUS will implement a research and innovation strategy over three years based upon five objectives:Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus.
Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners.
Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners.
Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes.
Objective 5: Raise the research profile of Eliava and the Twinning partners.
Status
SIGNEDCall topic
HORIZON-WIDERA-2023-ACCESS-02-01Update Date
22-11-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
